TODAY’S PATENT – METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA 

METHOD AND COMPOSITION FOR TREATING ALZHEIMER invention (US9943508B2) was invented by Thomas N. Chase and Kathleen E. Clarence-Smith and patented by USPTO on April 17^th, 2018. Currently, it stands assigned to Chase Pharmaceuticals Corp.

Unfortunately, existing cholinomimetic medications provide only limited clinical improvement for certain patients with the mentioned dementia disorders, even when given at their highest safe doses. This is the primary issue hindering the effectiveness of current AChEI therapy for Alzheimer’s-type dementias.

This invention suggests a better way to improve the effectiveness of traditional cholinergic treatments for Alzheimer’s-type dementia. It aims to reduce the common side effects of cholinomimetic treatments, like nausea and vomiting, by using non-anticholinergic antiemetic drugs. These drugs help decrease the adverse effects, allowing higher doses of cholinomimetic drugs to be used for better and longer-lasting results in treating dementia.

The goal is to provide a method for boosting the highest tolerated dose of an acetylcholine esterase inhibitor (AChEI) in Alzheimer’s patients without significant side effects, ultimately improving their symptoms.

Additionally, this invention offers the use of a non-anticholinergic antiemetic drug in making medicines for Alzheimer’s treatment alongside AChEI. This combination allows for a higher tolerated dose of AChEI, resulting in greater inhibition of acetylcholine esterase in the brain and improved dementia symptoms.